Effect of an Herbal Preparation, STW 5, in an Acute Model of Reflux Oesophagitis in Rats

被引:20
作者
Abdel-Aziz, Heba [1 ]
Zaki, Hala F. [2 ]
Neuhuber, Winfried [3 ]
Kelber, Olaf [4 ]
Weiser, Dieter [4 ]
Khayyal, Mohamed T. [2 ]
机构
[1] Heliopolis Univ, Fac Pharm, Dept Pharmacol, Cairo, Egypt
[2] Cairo Univ, Fac Pharm, Dept Pharmacol, Cairo, Egypt
[3] Univ Erlangen Nurnberg, Inst Anat, Erlangen, Germany
[4] Steigerwald Arzneimittelwerk GmbH, Dept Sci, Darmstadt, Germany
关键词
pyloric ligation; rat model; reflux oesophagitis; STW; 5; gastro-oesophageal reflux disease; FUNCTIONAL DYSPEPSIA; DOUBLE-BLIND; DISEASE; IBS; ADENOCARCINOMA; IBEROGAST(R); INFLAMMATION; ACTIVATION; FLAVONOIDS; METAPLASIA;
D O I
10.1254/jphs.09355FP
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
A multitarget herbal preparation, STW 5, has been used clinically in different gastrointestinal disorders including functional dyspepsia and irritable bowel syndrome. Previous studies have shown that it possesses properties that may render it useful in gastro-oesophageal reflux disease (GERD). We performed this study to test this compound in an acute model of reflux oesophagitis in rats. Oesophagitis was induced surgically by ligating the pyloric end and fore-stomach. Lower oesophageal pH was measured 3 h later in conscious animals. Five hours after surgery, animals were sacrificed and the oesophagi were examined macroscopically and histologically. Selected markers of inflammation were measured in oesophageal homogenates. STW 5 was given orally for 5 days before induction of oesophagitis. Pantoprazole was used as a reference standard. Ligated animals showed a high incidence of ulcerative lesions associated with a marked increase in myeloperoxidase, thiobarbituric acid reactive substances, tumor necrosis factor-alpha, and interleukin-1 beta. STW 5 did not affect oesophageal pH, but dose-dependently reduced the severity of the oesophageal lesions and normalized the deranged level of the inflammation markers. The beneficial effects were confirmed histopathologically. STW 5 proved to be effective in protecting against inflammatory lesions in this model of oesophagitis, thus warranting further investigation of its potential therapeutic usefulness in GERD.
引用
收藏
页码:134 / 142
页数:9
相关论文
共 52 条
[1]
NF-κB activation in Esophageal adenocarcinoma -: Relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy [J].
Abdel-Latif, MMM ;
O'Riordan, J ;
Windle, HJ ;
Carton, E ;
Ravi, N ;
Kelleher, D ;
Reynolds, JV .
ANNALS OF SURGERY, 2004, 239 (04) :491-500
[2]
Long-term Safety Concerns with Proton Pump Inhibitors [J].
Ali, Tauseef ;
Roberts, David Neil ;
Tierney, William M. .
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (10) :896-903
[3]
STW 5/Iberogast: Multi-target-action for treatment of functional dyspepsia and irritable bowel syndrome [J].
Allescher H.-D. ;
Wagner H.-U. .
Wiener Medizinische Wochenschrift, 2007, 157 (13-14) :301-307
[4]
Mechanisms of hypersensitivity in IBS and functional disorders [J].
Azpiroz, F. ;
Bouin, M. ;
Camilleri, M. ;
Mayer, E. A. ;
Poitras, P. ;
Serra, J. ;
Spiller, R. C. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2007, 19 :62-88
[5]
Emerging drugs for gastroesophageal reflux disease [J].
Boeckxstaens, G. E. .
EXPERT OPINION ON EMERGING DRUGS, 2009, 14 (03) :481-491
[6]
Bonaterra GA, 2008, PLANTA MED, V74, pPA295
[7]
CHAPMAN DB, 2010, J VOICE IN PRESS
[8]
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? [J].
Clark, DWJ ;
Strandell, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) :473-479
[9]
How does inflammation cause Barrett's metaplasia? [J].
Colleypriest, Benjamin J. ;
Ward, Stephen G. ;
Tosh, David .
CURRENT OPINION IN PHARMACOLOGY, 2009, 9 (06) :721-726
[10]
Epidemiology of gastrooesophageal reflux disease: A systematic review [J].
Dent, J ;
El-Serag, HB ;
Wallander, MA ;
Johansson, S .
GUT, 2005, 54 (05) :710-717